In Segment A, individuals will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Additional individuals are going to be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will receive oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. In https://abbv-744-brd4-inhibition58023.idblogz.com/32607666/detailed-notes-on-abbv-744-brd4-inhibitor-mechanism-of-action